Inputs: momentum, trendVelocity
Momentum 34/100 with trend velocity 42/100 — trend is rolling over.
Prediction result · Ensemble engineUpdated 5:45 AM
CYTKCytokinetics, Incorporated stock price outlook
$62.99-0.51% since prev closeNeutral
Cytokinetics, Incorporated (CYTK) is trading at $62.99, down 0.51% since the previous close and +2.87% over the past week. Price sits below its 50-day average by 6.68%, with price momentum at 34/100 and trend velocity at 42/100. Sentiment across 8 recent headlines reads net constructive at 58/100. Volatility risk is contained (41/100) and the stock is 16% of the way up its 52-week range. The weighted factor score lands at 34/100 — a neutral signal. Research only, not investment advice.
Universal leanmarket
CYTK
Cytokinetics, Incorporated
$62.99-0.51%
LEANNEUTRAL / wait for cleaner tape
WHY
- Cytokinetics, Incorporated (CYTK) is trading at $62.99, down 0.51% since the previous close and +2.87% over the past week. Price sits below its 50-day average by 6.68%, with price momentum at 34/100 and trend velocity at 42/100. Sentiment across 8 recent headlines reads net constructive at 58/100. Volatility risk is contained (41/100) and the stock is 16% of the way up its 52-week range. The weighted factor score lands at 34/100 — a neutral signal. Research only, not investment advice.
- Bull input: No bullish case in the sources.
- Bear input: Momentum 34/100 with trend velocity 42/100 — trend is rolling over.
RISK
Signals are model output from public data, not personalized investment advice.
INVALIDATE
Invalidate when a clear catalyst or directional print replaces the mixed tape.
AI Signal
Neutral · Strong edge
live data
Full public-market mode: chart history, quote, and news inputs were available.
Chart feed
Cron market chart feed
Quote/history
Six-month public chart history loaded.
News feed
8 relevant headlines found.
Signal inputs
Technical factors and news sentiment evaluated across multiple signal inputs.
News Sentiment58/100
Price Momentum34/100
Trend Velocity42/100
Volatility Risk41/100
Historical Modeling: Visualized ranges are mathematically derived from historic volatility metrics, corporate filings, and option-implied volume profiles. They represent statistical points of interest for research purposes, not financial execution commands or advice.
Why It Matters
Signal Explanation
Cytokinetics, Incorporated (CYTK) is trading at $62.99, down 0.51% since the previous close and +2.87% over the past week. Price sits below its 50-day average by 6.68%, with price momentum at 34/100 and trend velocity at 42/100. Sentiment across 8 recent headlines reads net constructive at 58/100. Volatility risk is contained (41/100) and the stock is 16% of the way up its 52-week range. The weighted factor score lands at 34/100 — a neutral signal. Research only, not investment advice.
Analyst Engine · Specialist model ensemble
Trees disagree — no clear lean on CYTK
Weighted factor score across 16 signal inputs evaluating 9 features: momentum, news, volume, volatility, range, sentiment divergence, trend structure, and oscillator. Consensus and weighting applied. Each specialist bot inspects a different slice of the feature set, casts a directional vote, and contributes a confidence weight to the final score.
Engine edgeStrong edgeNeutral
Inputs: newsSentiment, dayChange
Sentiment 58/100 + price -0.5% are both mid-range.
Inputs: unusualVolume, dayChange
Volume read 21/100 with price drift -0.5% — no clear footprint.
Inputs: volatilityRisk, momentum
Vol regime 41/100 is mid-range — no edge.
Inputs: pctOfRange, trendVelocity
Mid-range positioning — no edge from range alone.
Inputs: newsSentiment, weekChange
Sentiment 58/100 vs week change 2.9% are in agreement — no divergence edge.
Inputs: vsSma50, momentum
Price -6.7% under 50d SMA with no momentum reclaim — downtrend intact.
Inputs: momentum, trendVelocity
Oscillator at 38 — neutral zone.
Inputs: momentum, dayChange, vsSma50
Momentum 34/100 is not strong enough to confirm a breakout.
Inputs: newsSentiment, weekChange
News 58/100 and weekly change 2.9% do not create a clean follow-through read.
Inputs: unusualVolume, trendVelocity
Volume 21/100 does not show a dry-up signal.
Inputs: volatilityRisk, pctOfRange, momentum
Volatility 41/100 does not give a clean compression read.
Inputs: pctOfRange, dayChange, weekChange
Range position 16% is too middle-of-the-road to matter.
Inputs: newsSentiment, momentum, weekChange
Sentiment 58/100 and momentum 34/100 are not aligned enough for a clean read.
Inputs: vsSma50, momentum, trendVelocity
Price is still under the 50d SMA and the trend has not reclaimed control.
Inputs: momentum, trendVelocity, weekChange
Oscillator at 38 does not show a rebound edge.
Why the ensemble agrees
- Sentiment 58/100 + price -0.5% are both mid-range.
- Momentum 34/100 is not strong enough to confirm a breakout.
- Sentiment 58/100 and momentum 34/100 are not aligned enough for a clean read.
Counter-trees
- Momentum 34/100 with trend velocity 42/100 — trend is rolling over.
- Price -6.7% under 50d SMA with no momentum reclaim — downtrend intact.
Bull Case
- No bullish case in the sources.
Bear Case
- Momentum 34/100 with trend velocity 42/100 — trend is rolling over.
- Price -6.7% under 50d SMA with no momentum reclaim — downtrend intact.
- Price is still under the 50d SMA and the trend has not reclaimed control.
Latest Market Headlines
Headline titles only, from the publisher named on each card. Each links to the original story.
Yahoo! Finance Canada59
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
10/30/2026, 9:13:24 PM
Yahoo Finance Singapore52
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance Singapore
10/28/2026, 1:24:02 PM
Stocks Down Under49
Cytokinetics (NDQ:CYTK): Building the world’s first pure‑play myosin modulation platform - Stocks Down Under
10/27/2026, 6:42:20 PM
Simply Wall St62
Cytokinetics (CYTK) Could Be 43% Undervalued Following Health Canada Approval - Simply Wall St
10/28/2026, 11:55:06 PM
Yahoo Finance62
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
10/28/2026, 1:00:27 PM
Key stats
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Market cap
- $8.76B
- 52-week range
- $88.31/$58.05
- Volume
- 1,257,257
- Avg volume
- 1,866,383
- Analyst 1-yr target
- $105.00
- Exchange
- NASDAQ-GS
Source: Nasdaq public quote data. Research only.
Earnings Intelligence
Next
Nov 4, 2026
Estimate
$-1.5
Actual
$-1.5
- • Last report Aug 6, 2026 (Jun 2026): EPS $-1.5 vs $-1.63 expected, +7.98% surprise.
- • Beat estimates in 2 of the last 4 quarters.
- • Next report expected Nov 4, 2026, consensus EPS $-1.5 (Zacks estimate via Nasdaq; the company may confirm a different date).
Risk Warnings
- • Signals are model output from public data, not personalized investment advice.
- • Markets can move against any signal regardless of the score.
- • Confirm liquidity, spreads, and your own thesis before acting.
CYTK questions
What is the MarketPicks AI signal for Cytokinetics, Incorporated stock (CYTK)?
As of Nov 2, 12:45 AM ET, the ensemble reads neutral on CYTK — no consensus — 13 of 16 bots holding, with 0 bull, 3 bear and 13 hold votes from 16 specialist bots. Research only, not investment advice.
What is the latest CYTK price on MarketPicks?
CYTK was $62.99 on the latest quote (Nov 2, 12:45 AM ET), -0.51% since the previous close. Quotes can be delayed.
What do the momentum and trend scores for CYTK mean?
Scores run from 0 to 100, with 50 neutral. CYTK shows momentum 34/100, trend velocity 42/100 and volatility risk 41/100, with news sentiment at 58/100.
Not financial advice. MarketPicks.ai is an impersonal research tool. AI output can be wrong. Investing involves risk of loss. Do your own research and consult a licensed professional. Full disclaimer.